



Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026

DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:

- 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ET
- TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m. ET
- 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 10:30 a.m. ET

Audio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at <https://investor.jazzpharma.com/investors/events-presentations>. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts

Investors:

investorinfo@jazzpharma.com

Ireland +353 1 634 3211

U.S. +1 650 496 2717

Media:

CorporateAffairsMediaInfo@jazzpharma.com

Ireland +353 1 637 2141

U.S. +1 215 867 4948



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-upcoming-investor-conferences-302768975.html>

SOURCE Jazz Pharmaceuticals plc